For example, the three validated prognostic and predictive RNA-based multigene assays including OncotypeDx (21 gene assay), Mammoprint (70 gene assay), and Prosigna (50 gene assay) are used in the clinic to predict the efficacy of adjuvant chemotherapy in early stage hormone receptor-positive HER2-negative breast cancer [47]. This evidence concerns the gene ERBB2 and breast carcinoma.